Literature DB >> 24906849

Opioid needs of terminally ill patients with gynecologic malignancies.

Fumi Utsumi1, Hiroaki Kajiyama, Jun Sakata, Makiko Higashi, Kaoru Niimi, Ryuichiro Sekiya, Hiroko Mitsui, Shiro Suzuki, Tomokazu Umezu, Mika Mizuno, Eiko Yamamoto, Kiyosumi Shibata, Fumitaka Kikkawa.   

Abstract

BACKGROUND: Little is known about patterns and predictive factors regarding opioid use for terminally ill patients with gynecologic malignancies. The aim of this study was to elucidate predictors affecting opioid requirements of end-of-life patients with gynecologic malignancies.
METHODS: A retrospective study was carried out on patients with gynecological malignancies admitted to our institute and died during the years 2002 to 2012. The association between maximum opioid dose and factors affecting opioid requirements were examined. Data extracted from medical records included age, site of primary cancer, maximum total dose of opioids prescribed over 24 h, the site of recurrence and metastasis, procedures performed during the hospital stay, total number of chemotherapy courses and overall survival.
RESULTS: The study identified 189 patients. Most patients had ovarian cancer (42.3 %) followed by cervical cancer (28.0 %) and then corpus malignancy (27.0 %). Opioid requirements decreased with increasing age, especially from the 50s onward. This was particularly marked in cervical cancer patients. In addition, pelvic metastasis was associated with the maximum dose of opioids and the average opioid use was highest in patients with cervical cancer.
CONCLUSION: Young age and pelvic invasion were significant predictive factors regarding opioid requirements. Additionally, cervical cancer patients may require more opioids among those with gynecologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24906849     DOI: 10.1007/s10147-014-0708-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  24 in total

1.  Monitoring of opioid therapy in advanced cancer pain patients.

Authors:  S Mercadante; G Dardanoni; L Salvaggio; M G Armata; A Agnello
Journal:  J Pain Symptom Manage       Date:  1997-04       Impact factor: 3.612

2.  A cross-sectional survey of pain in palliative care in Portugal.

Authors:  Ferraz Gonçalves; Ana Almeida; Catarina Antunes; Maria Cardoso; Margarida Carvalho; Maria Claro; Francisca Coimbra; Inês Diniz; Bruno Fonseca; Emília Fradique; Edna Gonçalves; Florbela Gonçalves; Maria Gonçalves; Américo Magalhães; Paulo Pina; Conceição Pires; Paula Silva; Ricardo Silva; Rui Silva; Filipa Tavares; Laura Teixeira
Journal:  Support Care Cancer       Date:  2013-02-26       Impact factor: 3.603

3.  Factors influencing the opioid response in advanced cancer patients with pain followed at home: the effects of age and gender.

Authors:  S Mercadante; A Casuccio; S Pumo; F Fulfaro
Journal:  Support Care Cancer       Date:  2000-03       Impact factor: 3.603

4.  The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice.

Authors:  K Ikeda; T Kobayashi; T Ichikawa; T Kumanishi; H Niki; R Yano
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

5.  Pain and other symptoms and their relationship to quality of life in cancer patients on opioids.

Authors:  Sigridur Zoëga; Nanna Fridriksdottir; Valgerdur Sigurdardottir; Sigridur Gunnarsdottir
Journal:  Qual Life Res       Date:  2012-09-14       Impact factor: 4.147

6.  Pain prevalence in hospitalized patients in a German university teaching hospital.

Authors:  Barbara Strohbuecker; Herbert Mayer; George C M Evers; Rainer Sabatowski
Journal:  J Pain Symptom Manage       Date:  2005-05       Impact factor: 3.612

7.  Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.

Authors:  Columba Quigley; Simon Joel; Naina Patel; Amina Baksh; Maurice Slevin
Journal:  Palliat Med       Date:  2003-03       Impact factor: 4.762

Review 8.  Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

Authors:  M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn
Journal:  Ann Oncol       Date:  2007-03-12       Impact factor: 32.976

9.  The terminal cancer patient: effects of age, gender, and primary tumor site on opioid dose.

Authors:  Susannah Hall; Rollin M Gallagher; Edward Gracely; Calvin Knowlton; Douglas Wescules
Journal:  Pain Med       Date:  2003-06       Impact factor: 3.750

10.  Opioid needs of terminal care patients: variations with age and primary site.

Authors:  W D Rees
Journal:  Clin Oncol (R Coll Radiol)       Date:  1990-03       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.